ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1889

Modifications of Renal Function in Cancer Patients Undergoing Repeated and Frequent Administrations of Iodinated Contrast Medium (CM): A Multicentric Retrospective Study from Italy

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Cosmai, Laura, Aziende Socio Sanitarie Territoriale Fatebenefratelli Sacco, Milano, Lombardia, Italy
  • Pirovano, Marta, Universita degli Studi di Milano Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Milano, Lombardia, Italy
  • Re Sartò, Giulia Vanessa, Universita degli Studi di Milano Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Milano, Lombardia, Italy
  • Porta, Camillo, Universita degli Studi di Bari Aldo Moro, Bari, Puglia, Italy
  • Gallieni, Maurizio, Aziende Socio Sanitarie Territoriale Fatebenefratelli Sacco, Milano, Lombardia, Italy
Background

Contrast-enhanced computed tomography (CECT) is the imaging of choice for the diagnosis, staging, and follow-up of cancer patients, not to take into account its role to evaluate response to oncological treatments; in fact, it has been estimated that 47% of all CECTs are prescribed by Oncologists. Comorbidities, nephrotoxic concomitant medications, as well as chronic dehydration from different causes (nausea and vomiting, diarrhea, etc …) expose cancer patients to a higher risk of developing acute kidney injury (AKI) from CM. Risk factors, definition (PC-AKI vs CI-AKI) and preventive measures have been recently reconsidered, ultimately downsizing the incidence of this adverse event.

Methods

Aim of this study was to retrospectively assess the effects on renal function of repeated CM administrations in 407 oncological patients on active treatment, collected from 5 Italian oncology departments; patients should have undergone at least 3 CECT (on the average 3.5) within a single year (Fig I).

Results

According to our study, neither significant differences in eGFR values (calculated with the CKD-EPI formula) between the baseline and the different post-CECT timepoints, nor AKI cases (defined according to the RIFLE criteria), were recorded.

Conclusion

Repeated CM administrations in cancer patients did not lead to a worsening of renal function, confirming that CI-AKI has a significantly lower incidence than previously thought. Notably, 80% of the patients examined were found to be at low-risk, highlighting some kind of reluctance of Medical Oncologists and Radiologists to perform CECTs in these patients. On the contrary, the administration of CM could, and should, be freely used, in cancer patients, even in those at a higher risk.